Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity

Lung cancer is the major cause of cancer associated mortality. Mutations in EGFR have been implicated in lung cancer pathogenesis. Gefitinib (GF) is a RTKI (receptor tyrosine kinase inhibitor) first-choice drug for EGFR mutated advanced lung cancer. However, drug toxicity and cancer cell resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Mhone, Thomas Gabriel, Chen, Ming-Cheng, Kuo, Chia-Hua, Shih, Tzu-Ching, Yeh, Chung-Min, Wang, Tso-Fu, Chen, Ray-Jade, Chang, Yu-Chun, Kuo, Wei-Wen, Huang, Chih-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254481/
https://www.ncbi.nlm.nih.gov/pubmed/35813479
http://dx.doi.org/10.7150/ijbs.71870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254481/
https://www.ncbi.nlm.nih.gov/pubmed/35813479
http://dx.doi.org/10.7150/ijbs.71870

Ejemplares similares